Irinotecan, TAS-102 Plus Bevacizumab as a Third-Line or Beyond Therapy in mCRC Patients - Trial NCT06403709
Access comprehensive clinical trial information for NCT06403709 through Pure Global AI's free database. This Phase 2 trial is sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences and is currently Recruitment Completed. The study focuses on Metastatic Colorectal Cancer. Target enrollment is 35 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Irinotecan, Trifluridine/tipiracil (TAS-102) plus Bevacizumab
Interventional
drug
Sponsor & Location
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Timeline & Enrollment
Phase 2
Aug 01, 2022
Aug 01, 2026
Primary Outcome
Objective Response Rate (ORR)
Summary
Currently, the approved third-line treatments for metastatic colorectal cancer (mCRC) include
 regorafenib, fruquintinib, and trifluridine/tipiracil(TAS-102). In recent years, several
 phase I/II studies evaluated the combination of TAS-102 and bevacizumab in mCRC patients who
 were refractory to standard therapies and showed promising antitumor efficacy and manageable
 toxicity. In this single-center phase II study, the investigators explored the efficacy and
 safety of irinotecan, TAS-102, plus bevacizumab in a third-line or beyond therapy for
 patients with mCRC.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06403709
Non-Device Trial